AI in MedTech: Why good algorithms alone are useless and what really determines success
Artificial intelligence is no longer a vision of the future in medical technology. Today, AI-powered systems assist with diagnoses, prioritize patient cases, and guide treatments. In many areas, they are already in clinical use or are on the verge of approval. And yet, a surprising number of AI projects in the medtech sector fail.
The reason rarely lies in the quality of the algorithms. Much more often, it is systemic causes that slow down or completely block projects. Technically powerful models encounter product architectures, data structures, and regulatory processes that are not designed for AI.
A common misconception is the assumption that a well-validated model alone automatically results in a marketable product. In medical technology, AI is never an isolated component but always part of an overall system. And this system must be manageable from a regulatory, technical, and organizational standpoint.
There are several typical patterns that recur in failed AI projects. A particularly common trigger is the so-called “dataset shift.” Models are trained on data that is not representative of their later use. In the lab, they deliver impressive results, but in field operations, performance drops significantly. Without suitable data architecture and monitoring concepts, this drop in performance remains undetected for a long time.
Another critical issue is the regulatory classification at the start of the project. If an AI function is classified too late or too optimistically, it results in massive documentation and validation efforts down the line. Clear qualification decisions are essential, particularly for hybrid systems in which AI is embedded in clinical workflows.
Furthermore, the post-market phase is often underestimated in many projects. Traditional software development frequently ends with the market launch. For AI-based medical devices, however, this marks the beginning of a safety-critical phase. Models change their performance characteristics during operation, for example due to new patient cohorts or altered data distributions. Without structured monitoring, this change only becomes apparent once it becomes clinically relevant.
These technical and organizational challenges intersect with a regulatory environment that is subject to constant change. With the EU AI Act, a binding legal framework specifically for AI systems has emerged for the first time, running parallel to existing MDR regulations. For medtech manufacturers, this introduces a new level of complexity that quickly overwhelms traditional development and approval approaches.
It is clear that successful medical devices incorporating AI do not result from an “AI-first” approach. What is crucial is a “regulatory-by-design” approach, in which regulatory requirements are integrated into the architecture, data management, and development processes from the very beginning. This is the only way to effectively combine technical performance, clinical safety, and regulatory compliance.
AI in medtech is therefore not an isolated innovation project. It has a long-term product lifecycle that must be strategically planned and systematically implemented. Taking this into account not only increases the chances of successful approval but also ensures stable and safe systems in everyday clinical practice.
The white paper “AI in Medical Devices: Safe Integration, Validated Approval” explains these relationships in detail and identifies the factors that determine success or failure.
